Effect of supplementation in treatment of women with polycystic ovary syndrome

Phase 3

Conditions: E28.2
Polycystic ovary syndrome.
Sclerocystic ovary syndrome Stein-Leventhal syndrome

Registration Number: IRCT201508025623N50

Lead Sponsor: Vice chancellor for research, Arak University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Complete

Sex: Female

Target Recruitment: 60

Inclusion Criteria

Women aged 18-40 years
Diagnosed with PCOS

Exclusion Criteria

T2DM
Liver disease
History of cardiac or renal failure
Thyroid disease
Adrenal hyperplasia
Intake of antiobesity and antidepressants in the last 3 months
Smoking
Taking other forms of probiotics including probiotic yogurt, kefir and other fermented foods
Taking antibiotics.

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Insulin. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Elisa kit.;Insulin resistance. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Calculated according to the formula.;Insulin sensitivity. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Calculated according to the formula.

Secondary Outcome Measures

Name	Time	Method
Triglycerides. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;Fasting blood sugar. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;HDL-cholesterol. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;Total cholesterol. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;VLDL. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;LDL. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;Weight loss. Timepoint: 12 weeks after the intervention. Method of measurement: Scale.;Body mass index loss. Timepoint: 12 weeks after the intervention. Method of measurement: Calculated according to the formula.